Skip to main content

Peer Review reports

From: Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy

Original Submission
20 Dec 2021 Submitted Original manuscript
27 Dec 2021 Reviewed Reviewer Report
4 Feb 2022 Reviewed Reviewer Report
7 Feb 2022 Reviewed Reviewer Report
7 Feb 2022 Reviewed Reviewer Report
16 Mar 2022 Author responded Author comments - Yue Liu
Resubmission - Version 2
16 Mar 2022 Submitted Manuscript version 2
17 Mar 2022 Reviewed Reviewer Report
17 Mar 2022 Reviewed Reviewer Report
22 Mar 2022 Reviewed Reviewer Report
26 Mar 2022 Author responded Author comments - Yue Liu
Resubmission - Version 3
26 Mar 2022 Submitted Manuscript version 3
Publishing
28 Mar 2022 Editorially accepted
6 May 2022 Article published 10.1186/s12916-022-02357-6

You can find further information about peer review here.

Back to article page